About: Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade) Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The aim of this study was to investigate if Thalidomide or Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers in patients with relapsed multiple myeloma (MM). We have focused on four chromosomal aberrations known as negative prognostic factors in MM treated by conventional or myeloablative treatment: deletion of 13q14, deletion of 17p13 (p53), translocation t(4;14) and amplification of CKS1B gene (amp1q21). We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Two groups of patients with relapsed multiple myeloma of similar age, sex, stage of the disease and other parameters were treated by Thalidomide based regimens (24 patients) and by Bortezomib based regimens (18 patients). The aim of this study was to investigate if Thalidomide or Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers in patients with relapsed multiple myeloma (MM). We have focused on four chromosomal aberrations known as negative prognostic factors in MM treated by conventional or myeloablative treatment: deletion of 13q14, deletion of 17p13 (p53), translocation t(4;14) and amplification of CKS1B gene (amp1q21). We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Two groups of patients with relapsed multiple myeloma of similar age, sex, stage of the disease and other parameters were treated by Thalidomide based regimens (24 patients) and by Bortezomib based regimens (18 patients). (en)
Title	Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade) Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade) (en)
skos:prefLabel	Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade) Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade) (en)
skos:notation	RIV/00216224:14110/07:00022440!RIV10-MSM-14110___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(LC06027), Z(MSM0021622415)
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Pour, Luděk Kuglík, Petr Hájek, Roman Adam, Zdeněk Němec, Pavel Filková, Hana Oltová, Alexandra Grešliková, Henrieta Zaoralová, Romana
http://linked.open.../riv/druhVysledku	D - Článek ve sborníku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	413908
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/07:00022440
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Multiple myeloma; cIg-FISH; 13q deletion; p53 deletion; t(4; 14); amp1q21; Velcade; Thalidomide (en)
http://linked.open.../riv/klicoveSlovo	13q deletion 14) amp1q21 p53 deletion Velcade Multiple myeloma Thalidomide t(4 cIg-FISH
http://linked.open...ontrolniKodProRIV	[62B7BF41C1C8]
http://linked.open...v/mistoKonaniAkce	Instanbul
http://linked.open...i/riv/mistoVydani	Netherlands
http://linked.open...i/riv/nazevZdroje	Chromosome Research
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	9 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...vavai/riv/projekt	University Research Centre - Czech Myeloma Group
http://linked.open...UplatneniVysledku	2007
http://linked.open...iv/tvurceVysledku	Adam, Zdeněk Hájek, Roman Kuglík, Petr Pour, Luděk Němec, Pavel Krejčí, M. Filková, Hana Oltová, Alexandra Grešliková, Henrieta Zaoralová, Romana
http://linked.open...vavai/riv/typAkce	WRD - Světová
http://linked.open.../riv/zahajeniAkce	2007-07-07 (xsd:date)
http://linked.open...n/vavai/riv/zamer	Molecular basis of cell and tissue regulations
issn	0967-3849
number of pages	2 (xsd:int)
http://purl.org/ne...btex#hasPublisher	Springer-Verlag
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software